sFRP1 Expression Regulates Wnt Signaling in Chronic Myeloid Leukemia K562 Cells
Melek Pehlivan1, Ceyda Caliskan2, Zeynep Yuce2
1Vocational School of Health Services, Izmir Katip Celebi University, Izmir, Turkey.
Background:
Wnt signaling cascades play important roles in cell fate decisions and their deregulation has been documented in many diseases, including malignant tumors and leukemia. One mechanism of aberrant Wnt signaling is the silencing of Wnt inhibitors through epigenetic mechanisms. The sFRPs are one of the most studied Wnt inhibitors; and the sFRP1 loss is known in many hematological malignancies. Therefore, we aimed to compare the expression of Wnt related genes in the presence and absence of sFRP1 in a chronic myeloid leukemia (CML) cell line.
Objective:
It is important to understand how sFRP1 and sFRP1 perform their effects on CML to design new agents and strategies for resistant and advanced forms of CML.
Materials And Methods:
We used K562 cells, which normally do not express sFRP1 and its sFRP1 expressing subclone K562s. Total RNA was isolated from K562 and K562s cell lines and converted to cDNA. PCR Array experiments were performed using Human Wnt Signaling Pathway Plus RT2 Profiler™ kit. Wnt signaling pathway activation was studied by western blot for downstream signaling targets.
Results:
The WNT3, LRP6, PRICKLE1 and BTRC expressions were significantly decreased in the presence of sFRP1; while WNT5B increased. The sFRP1 expression inhibited stabilization of total β-catenin protein and downstream effector phosphorylation of noncanonical Wnt/PCP signaling; whereas Ca2+/PKC signaling remained active.
Conclusion:
The results suggest that sFRP1 could be a promising therapeutic anticancer agent. Defining these pathway interactions is crucial for designing new agents resistant and advanced forms of CML.
Insights
Secreted frizzled-related protein 1 (sFRP1) loss is common in hematological malignancies. This study investigated Wnt signaling gene expression in chronic myeloid leukemia (CML) cells with and without sFRP1, revealing potential therapeutic targets.
Area of Science:
- Molecular Biology
- Cancer Biology
- Signal Transduction
Background:
- Wnt signaling pathways are crucial for cell fate and implicated in diseases like leukemia.
- Epigenetic silencing of Wnt inhibitors, such as secreted frizzled-related protein 1 (sFRP1), contributes to aberrant Wnt signaling.
- Loss of sFRP1 is observed in various hematological malignancies, highlighting its potential role.
Purpose of the Study:
- To compare Wnt-related gene expression in chronic myeloid leukemia (CML) cells with and without sFRP1.
- To elucidate the functional impact of sFRP1 on Wnt signaling pathways in CML.
- To identify potential therapeutic strategies for advanced and resistant CML forms.
Main Methods:
- Utilized K562 cells and an sFRP1-expressing subclone (K562s).
- Performed PCR Array analysis using the Human Wnt Signaling Pathway Plus RT2 Profiler™ kit.
- Assessed Wnt signaling pathway activation via Western blot for downstream targets, including beta-catenin.
Main Results:
- sFRP1 presence significantly decreased WNT3, LRP6, PRICKLE1, and BTRC expression while increasing WNT5B.
- sFRP1 inhibited beta-catenin stabilization and downstream phosphorylation in noncanonical Wnt/PCP signaling.
- Calcium/protein kinase C (Ca2+/PKC) signaling pathways remained active despite sFRP1 expression.
Conclusions:
- sFRP1 demonstrates potential as a therapeutic anticancer agent for CML.
- Understanding sFRP1's pathway interactions is vital for developing novel treatments for resistant CML.
- Targeting sFRP1-modulated pathways could offer new strategies for advanced hematological malignancies.
Related Concept Videos
02:54Canonical Wnt Signaling Pathway
01:41Non-Canonical Wnt Signaling Pathways
02:23Abnormal Proliferation
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...